AC Immune S.A.

ACIU

Cena:

$ 2.83

-0.02 (-0.70%)

Valuace

Růst

Zdraví

Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři

Souhrn

Finanční data

Pro investory

Předpovědi

Zprávy

Dividendy

Zisky

Návštěvnost webu

Akcionáři

Zprávy

Zahraniční články

Tiskové zprávy

Dokumenty ke stáhnutí

Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care

7:01 15-05-2026

Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contri...

AC Immune (ACIU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

10:55 14-05-2026

AC Immune (ACIU) appears to have found support after losing some value lately, as indicated by the f...

AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates

9:30 30-04-2026

AC Immune (ACIU) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estima...

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

7:00 30-04-2026

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherap...

ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know

11:31 09-04-2026

AC Immune stock gains after expansion of its agreement with LLY, adding next-generation Tau Morphome...

Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?

10:40 09-04-2026

Here is how AC Immune (ACIU) and Assertio (ASRT) have performed compared to their sector so far this...

Why AC Immune Stock Zoomed Almost 15% Higher Today

16:54 07-04-2026

This will help fund the biotech's development of a unique treatment for neurodegenerative diseases l...

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

7:00 07-04-2026

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly Ame...

AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's

12:47 11-12-2025

AC Immune SA (NASDAQ: ACIU) on Thursday released interim safety and efficacy results from the Phase ...

AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates

9:55 04-11-2025

AC Immune (ACIU) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimat...

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

7:00 04-11-2025

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Sharpened inv...

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

11:01 28-10-2025

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earni...

AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates

9:16 05-08-2025

AC Immune (ACIU) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estima...

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

7:00 05-08-2025

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active...

AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

11:05 29-07-2025

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earni...

AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates

9:15 30-04-2025

AC Immune (ACIU) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estima...

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

7:00 30-04-2025

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to...

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

7:00 25-03-2025

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD...

ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?

16:01 24-03-2025

AC Immune's shares decline 18.3% in a month. While the company's pipeline progress is encouraging, w...

AC Immune (ACIU) Upgraded to Strong Buy: Here's What You Should Know

13:00 05-03-2025

AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism abou...

AC IMMUNE POSITIVE INTERIM PHASE 2 DATA ON ACI-7104.056 SUPPORT POTENTIAL SLOWING OF PROGRESSION OF PARKINSON'S DISEASE

11-12-2025

THE RESULTS SHOW, FOR THE FIRST TIME, THAT TARGETING A-SYN PATHOLOGY WITH AN ACTIVE IMMUNOTHERAPY CO...

Více zde

AC IMMUNE REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

04-11-2025

AC IMMUNE REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE SHARPENED INV...

Více zde

FIRST CHARACTERIZATION OF A TDP-43 PET TRACER PUBLISHED IN NATURE COMMUNICATIONS SHOWING POTENTIAL OF AC IMMUNE'S ACI-19626 IN PRECISION MEDICINE

24-10-2025

FIRST CHARACTERIZATION OF A TDP-43 PET TRACER PUBLISHED IN NATURE COMMUNICATIONS SHOWING POTENTIAL O...

Více zde

AC IMMUNE REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

05-08-2025

AC IMMUNE REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE THREE ACTIVE...

Více zde

AC IMMUNE REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

30-04-2025

AC IMMUNE REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE CONTINUING TO...

Více zde

AC IMMUNE REPORTS FURTHER POSITIVE INTERIM RESULTS FROM PHASE 2 TRIAL OF ACI-7104.056 ACTIVE IMMUNOTHERAPY IN EARLY PARKINSON'S DISEASE

02-04-2025

AC IMMUNE REPORTS FURTHER POSITIVE INTERIM RESULTS FROM PHASE 2 TRIAL OF ACI-7104.056 ACTIVE IMMUNOT...

Více zde

AC IMMUNE ANNOUNCES UPCOMING PRESENTATIONS AND INDUSTRY SYMPOSIUM ON ACTIVE IMMUNOTHERAPIES AT AD/PD™ 2025

25-03-2025

AC IMMUNE ANNOUNCES UPCOMING PRESENTATIONS AND INDUSTRY SYMPOSIUM ON ACTIVE IMMUNOTHERAPIES AT AD/PD...

Více zde

AC IMMUNE REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

13-03-2025

AC IMMUNE REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE LANDMARK EXCLUSIV...

Více zde

AC IMMUNE UNVEILS NOVEL THERAPEUTIC ANTIBODY DRUG CONJUGATE (ADC) TECHNOLOGY FOR IMPROVED EFFICACY IN NEURODEGENERATIVE DISEASES AT AAIC 2024

31-07-2024

AC IMMUNE UNVEILS NOVEL THERAPEUTIC ANTIBODY DRUG CONJUGATE (ADC) TECHNOLOGY FOR IMPROVED EFFICACY I...

Více zde

AC IMMUNE'S ACI-35.030 (NOW “JNJ-2056”) GRANTED FDA FAST TRACK DESIGNATION FOR ALZHEIMER'S DISEASE

25-07-2024

AC IMMUNE'S ACI-35.030 (NOW “JNJ-2056”) GRANTED FDA FAST TRACK DESIGNATION FOR ALZHEIMER'S DISEA...

Více zde

AC IMMUNE TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN JUNE 2024

28-05-2024

AC IMMUNE TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN JUNE 2024 LAUSANNE, SWITZERLAN...

Více zde

AC IMMUNE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

13-05-2024

AC IMMUNE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE LANDMARK DEAL...

Více zde

AC IMMUNE AND TAKEDA SIGN EXCLUSIVE OPTION AND LICENSE AGREEMENT FOR ACTIVE IMMUNOTHERAPY TARGETING AMYLOID BETA FOR ALZHEIMER'S DISEASE

13-05-2024

AC IMMUNE AND TAKEDA SIGN EXCLUSIVE OPTION AND LICENSE AGREEMENT FOR ACTIVE IMMUNOTHERAPY TARGETING ...

Více zde

AC IMMUNE REPORTS FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

14-03-2024

AC IMMUNE REPORTS FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE ACI-24.060 ABATE ...

Více zde

AC IMMUNE ANNOUNCES UPCOMING PRESENTATIONS AT AD/PD™ 2024

22-02-2024

AC IMMUNE ANNOUNCES UPCOMING PRESENTATIONS AT AD/PD™ 2024 MULTIPLE PRESENTATIONS AT THE INTERNATIO...

Více zde

AC IMMUNE TO REGAIN GLOBAL RIGHTS TO CRENEZUMAB AND SEMORINEMAB

22-01-2024

AC IMMUNE TO REGAIN GLOBAL RIGHTS TO CRENEZUMAB AND SEMORINEMAB COMPANY'S STRATEGY IS FOCUSED ON ADV...

Více zde

AC IMMUNE PROGRESS UPDATE ON PHASE 2 ACTIVE IMMUNOTHERAPY CLINICAL PIPELINE FOR ALZHEIMER'S AND PARKINSON DISEASES

03-01-2024

AC IMMUNE PROGRESS UPDATE ON PHASE 2 ACTIVE IMMUNOTHERAPY CLINICAL PIPELINE FOR ALZHEIMER'S AND PARK...

Více zde

AC IMMUNE ANNOUNCES PRICING OF UNDERWRITTEN OFFERING OF COMMON SHARES

15-12-2023

AC IMMUNE ANNOUNCES PRICING OF UNDERWRITTEN OFFERING OF COMMON SHARES LAUSANNE, SWITZERLAND, DECEMBE...

Více zde

AC IMMUNE'S TARGETED ANTI-PTAU ACTIVE IMMUNOTHERAPY FOR ALZHEIMER'S DISEASE ADVANCES INTO PHASE 2B TRIAL

15-12-2023

AC IMMUNE'S TARGETED ANTI-PTAU ACTIVE IMMUNOTHERAPY FOR ALZHEIMER'S DISEASE ADVANCES INTO PHASE 2B T...

Více zde

AC IMMUNE STRENGTHENS MANAGEMENT, APPOINTS MADIHA DEROUAZI AS CSO AND CHRISTOPHER ROBERTS AS CFO

01-12-2023

AC IMMUNE STRENGTHENS MANAGEMENT, APPOINTS MADIHA DEROUAZI AS CSO AND CHRISTOPHER ROBERTS AS CFO OUT...

Více zde

AC IMMUNE TO PRESENT AT THE JEFFERIES 2023 LONDON HEALTHCARE CONFERENCE

07-11-2023

AC IMMUNE TO PRESENT AT THE JEFFERIES 2023 LONDON HEALTHCARE CONFERENCE LAUSANNE, SWITZERLAND, NOVEM...

Více zde

AC IMMUNE REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

03-11-2023

AC IMMUNE REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE RESULTS FROM ...

Více zde

AC IMMUNE TO HOST KOL WEBINAR ON AMYLOID PLAQUE PET IMAGING IN ALZHEIMER'S DISEASE AS A SURROGATE OF CLINICAL EFFICACY ON NOVEMBER 9, 2023

02-11-2023

AC IMMUNE TO HOST KOL WEBINAR ON AMYLOID PLAQUE PET IMAGING IN ALZHEIMER'S DISEASE AS A SURROGATE OF...

Více zde

AC IMMUNE CLINICAL DATA PUBLISHED IN NATURE COMMUNICATIONS SHOW ALPHA-SYNUCLEIN PET TRACER ACI-12589 HAS POTENTIAL AS NEURODEGENERATIVE DISEASE DIAGNOSTIC

27-10-2023

PRESS RELEASE...

Více zde

AC IMMUNE ANNOUNCES UPCOMING PRESENTATIONS AT THE 16TH CTAD CONFERENCE

17-10-2023

AC IMMUNE ANNOUNCES UPCOMING PRESENTATIONS AT THE 16 TH CTAD CONFERENCE...

Více zde

AC IMMUNE TO PRESENT AT THE JEFFERIES 2023 CNS & NEURO SUMMIT IN OCTOBER 2023

05-10-2023

AC IMMUNE TO PRESENT AT THE JEFFERIES 2023 CNS & NEURO SUMMIT IN OCTOBER 2023 LAUSANNE, SWITZERLAND,...

Více zde

AC IMMUNE TO PRESENT AT THE H.C. WAINWRIGHT 25TH ANNUAL GLOBAL INVESTMENT CONFERENCE IN SEPTEMBER 2023

05-09-2023

AC IMMUNE TO PRESENT AT THE H.C. WAINWRIGHT 25TH ANNUAL GLOBAL INVESTMENT CONFERENCE IN SEPTEMBER 20...

Více zde

AC IMMUNE REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

04-08-2023

AC IMMUNE REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE...

Více zde

AC IMMUNE TO PRESENT AT THE BTIG VIRTUAL BIOTECHNOLOGY CONFERENCE 2023

28-07-2023

AC IMMUNE TO PRESENT AT THE B TIG VIRTUAL BIOTECHNOLOGY CONFERENCE 2023...

Více zde

AC IMMUNE SA APPOINTS NEW CHIEF MEDICAL OFFICER

26-07-2023

AC IMMUNE SA APPOINTS NEW CHIEF MEDICAL OFFICER NUNO MENDONÇA, MD APPOINTED NEW CHIEF MEDICAL OFFIC...

Více zde

Dokumenty nejsou k dispozici